Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
|Articles|July 9, 2012
CMS Proposes 0.1% Cut to Home Health Medicare Reimbursement
Advertisement
The CMS is proposing that home health Medicare reimbursement be cut by 0.1% in 2013, that requirements be established for unannounced, standard and extended surveys of home health agencies and that new alternative sanctions be created for home health agencies that are out of compliance.
Read the full story:
Source: ModernHealthcare.com
The proposed rule, published on the Office of the Federal Register's website Friday, also would create new survey and certification requirements for home health agencies including definitions for types of surveys, survey frequency, surveyor qualifications, and an opportunity for informal dispute resolution, according to a CMS news release.
Advertisement
Related to this article
CMS finalized Transparency in Coverage updates as a researcher warns ghost rates and missing inpatient data limit payer price files.
Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.
A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.
The opening session of AAO 2026 featured a keynote speech discussing how artificial intelligence (AI) will play a part in health care.
Incidence of diabetic macular edema and the need for glaucoma surgery were reduced after treatment with glucagon-like peptide-1 receptor agonists.
TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.
Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
A New Mechanism for DME in the BRUNELLO Trial: Donald J. D’Amico, MD
3
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
4
Full POLARGO Data Reveal OS, Safety for Pola-R-GemOx in DLBCL
5